FULCRUM THERAPEUTICS, INC. Stock Split Ratio
FULCRUM THERAPEUTICS, INC. (FULC) reported Stock Split Ratio of 14.29% for the 0-month period ending 2019-07-05, per its 10-K filed 2020-03-05.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2020-03-05
- 2019-07-05: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 14.29%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month |
|---|---|
| 2019-07-05 | 14.29% 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |